茚达特罗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "茚达特罗" in Chinese language version.

refsWebsite

Global rank Chinese rank

1^st place

68^th place

209^th place

4^th place

5^th place

2^nd place

23^rd place

447^th place

581^st place

11^th place

332^nd place

low place

doi.org

Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775.
Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. May 2007, 29 (5): 871–8. PMID 17251236. doi:10.1183/09031936.00060006 .
Geake, James B. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Reviews. 2015, 1 (3): CD010139. PMC 6464646 . PMID 25575340. doi:10.1002/14651858.CD010139.pub2.

Faulkner, Sarah. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Drug Delivery Business. 22 December 2016 [2024-05-23]. （原始内容存档于2021-10-31）.

Onbrez Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
Oslif Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
Hirobriz Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
European Public Assessment Report for Onbrez Breezhaler 互联网档案馆的存檔，存档日期2010-01-16.

FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (新闻稿). U.S. Food and Drug Administration. 2011-07-01 [2011-07-02]. （原始内容存档于2011-07-03）.

Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383. U.S. Food and Drug Administration. 13 August 2013 [14 June 2021]. （原始内容存档于2021-04-07）.

Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775.
Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. May 2007, 29 (5): 871–8. PMID 17251236. doi:10.1183/09031936.00060006 .
Geake, James B. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Reviews. 2015, 1 (3): CD010139. PMC 6464646 . PMID 25575340. doi:10.1002/14651858.CD010139.pub2.

Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. July 2005, 14 (7): 775–83. PMID 16022567. S2CID 11930383. doi:10.1517/13543784.14.7.775.

Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011. DailyMed. 1 April 2020 [14 June 2021]. （原始内容存档于2021-06-15）.
Onbrez Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
Oslif Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
Hirobriz Breezhaler EPAR. European Medicines Agency (EMA). 17 September 2018 [20 January 2021]. （原始内容存档于2021-01-28）.
European Public Assessment Report for Onbrez Breezhaler 互联网档案馆的存檔，存档日期2010-01-16.
FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (新闻稿). U.S. Food and Drug Administration. 2011-07-01 [2011-07-02]. （原始内容存档于2011-07-03）.
Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383. U.S. Food and Drug Administration. 13 August 2013 [14 June 2021]. （原始内容存档于2021-04-07）.
Faulkner, Sarah. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Drug Delivery Business. 22 December 2016 [2024-05-23]. （原始内容存档于2021-10-31）.